Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
Public ClinicalTrials.gov record NCT02996500. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12 WEEK RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PARALLEL GROUP, ACTIVE AND PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY PROFILE OF PF-06650833 IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATE
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, randomized, double blind, double dummy, placebo and active-controlled, parallel group study to assess the efficacy and safety of PF 06650833 at Week 12 in subjects with moderate-severe, active, RA who have had an inadequate response to MTX. PF-06650833 or matching placebo tablets will be administered orally QD under fasting conditions, and tofacitinib or matching tofacitinib placebo tablets will be administered orally BID for 12 weeks in a blinded fashion.
Study identification
- NCT ID
- NCT02996500
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 269 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2016 (Actual)
- Primary completion
- Aug 15, 2018 (Actual)
- Completion
- Aug 15, 2018 (Actual)
- Last update posted
- Feb 27, 2020
2016 – 2018
United States locations
- U.S. sites
- 15
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical and Translational Research Center of Alabama, PC | Tuscaloosa | Alabama | 35406 | — |
| Dory Hardy, PharmD | Tucson | Arizona | 85723 | — |
| Southern Arizona VA Health care System | Tucson | Arizona | 85723 | — |
| Robert W. Levin, MD,PA | Clearwater | Florida | 33765 | — |
| Millennium Research | Ormond Beach | Florida | 32174 | — |
| Arthritis & Rheumatic Care Center | South Miami | Florida | 33143 | — |
| Qps-Mra, Llc | South Miami | Florida | 33143 | — |
| Medical Associates of North Georgia | Canton | Georgia | 30115 | — |
| Graves Gilbert Clinic | Bowling Green | Kentucky | 42101 | — |
| Arthritis and Diabetes Clinic, Inc. | Monroe | Louisiana | 71203 | — |
| Ramesh C Gupta, M.D. | Memphis | Tennessee | 38119 | — |
| Accurate Clinical Management, LLC | Baytown | Texas | 77521 | — |
| Accurate Clinical Management, LLC | Houston | Texas | 77004 | — |
| Accurate Clinical Management, LLC | Houston | Texas | 77084 | — |
| DM Clinical Research | Tomball | Texas | 77375 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 88 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02996500, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 27, 2020 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02996500 live on ClinicalTrials.gov.